RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype
This important study, called RAR-Immune, is looking into new ways to treat advanced sarcomas that are rare, have spread, or cannot be removed by surgery. It's a phase 3 trial, meaning it's in the final stages of testing before a new treatment might become widely available. Patients will be randomly assigned to one of two groups. One group will receive a combination of two medicines, nivolumab and ipilimumab, which are types of immunotherapy that help your own immune system fight cancer. The other group will receive pazopanib, a different cancer drug. Researchers will compare how well both treatments work to stop the cancer from getting worse and to improve overall health and quality of life.
At a glance
What is this study about?
This study, called RAR-Immune, is a clinical trial focusing on advanced sarcomas. Sarcomas are a type of cancer that can develop in various parts of the body, including bone, muscle, fat, and cartilage. "Advanced" means the cancer has either spread to other parts of the body (this is called metastatic) or it's in a place where surgery isn't possible (unresectable).
The trial is specifically for *rare* types of sarcoma. Because these cancers are uncommon, it can be challenging to find the best treatment. This study is a "Phase III" trial, which means it's a large, important study comparing a new treatment or combination of treatments against the current standard approach to see which is more effective and safer. The goal is to find out if the new treatment offers a better chance of managing the cancer.
Patients in this study will receive one of two treatments: either a combination of two immunotherapy drugs (nivolumab and ipilimumab) or a single drug called pazopanib. Immunotherapy works by boosting your body's own immune system to fight cancer cells. Pazopanib works differently, by blocking signals that cancer cells need to grow. The main thing the researchers want to find out is how long people live without their cancer getting worse, but they'll also be looking at other important aspects like overall survival, how many people respond to the treatment, and how their quality of life is affected.
Key takeaways
- Compares two treatments for rare, advanced sarcomas.
- One group gets two immunotherapy drugs (nivolumab + ipilimumab), the other gets pazopanib.
- Aims to see which treatment stops cancer from growing for longer.
- Also looks at overall survival and quality of life.
- You must be 18 or older with a rare, advanced sarcoma.
Who may be eligible?
To join any clinical study, there are specific guidelines about who can and cannot take part. These guidelines help the researchers make sure the study results are clear and reliable, and importantly, they help keep participants safe.
For the RAR-Immune study, you must be at least 18 years old. There's no upper age limit. The study is open to both men and women.
The most important criteria relate to your diagnosis: you must have an advanced sarcoma that is considered rare, has spread to other parts of your body (metastatic), or cannot be removed through surgery (unresectable). Other medical details about your overall health, previous treatments, and how well your body systems are working will also be carefully reviewed by the study team to ensure the trial is right for you.
- Are you 18 years old or older?
- Do you have a diagnosis of a rare sarcoma?
- Has your sarcoma spread (metastatic) or can it not be removed by surgery (unresectable)?
- Are you able to attend regular hospital appointments?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you will first go through some screening tests to confirm you meet all the eligibility requirements. If you qualify, you will be randomly assigned to one of two treatment groups – like flipping a coin, but done by a computer. This means neither you nor your doctor can choose which treatment you receive. You will either get the nivolumab plus ipilimumab combination, or pazopanib alone.
Throughout the study, you will have regular visits to the hospital or clinic. These visits will involve blood tests, physical examinations, and scans (like CT or MRI scans) to monitor your health and how your cancer is responding to treatment. You will also be asked to complete questionnaires about your quality of life. The treatment will continue as long as it is helping you and you are not experiencing severe side effects. After treatment stops, you will have follow-up visits to continue to monitor your health and long-term outcomes. The total duration of your participation will depend on how you respond to treatment and the long-term follow-up schedule.
Potential risks and benefits
Locations (1)
- —France
Common questions
What is randomisation?
Randomisation means that a computer will decide which treatment group you are in, like flipping a coin. This ensures the study is fair and the results are reliable.
What is a 'rare' sarcoma?
A rare sarcoma is a type of sarcoma that is not commonly diagnosed. The trial focuses on these specific types of cancer.
What does 'metastatic or unresectable' mean?
'Metastatic' means the cancer has spread to other parts of your body. 'Unresectable' means that surgery isn't an option to remove the cancer.
Will I know which treatment I'm getting?
Yes, in this type of study, you and your doctors will know which treatment you are receiving (either the drug combination or pazopanib).
What if I get side effects?
The study team will monitor you closely for any side effects and provide care to help manage them. You can also discuss any concerns with your medical team at any time.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.